Moscow, Russia
Petrovax Pharm is a Russian full-cycle biotechnological company with 25 years of successful market experience. The company's product portfolio includes original pharmaceutical products, localized drugs and vaccines, localized medicinal products, as well as contract medicines and food supplements.
The company has a research center and holds patents for new molecules and pharmaceutical manufacturing technologies in Russia and abroad. Petrovax’s investment program provides the financing of advanced R&D projects.
Petrovax's modern manufacturing complex for substance and finished dosage forms production located in Moscow Region operates in full compliance with the EAEU and EU GMP standards. The production capacity provides for manufacturing more than 160 million doses of immunobiological products per year.
For ten years, the company has successfully confirmed compliance with the GMP EU certificate (Slovakia), which was first obtained in 2012. Petrovax is one of the largest Russian exporters of influenza vaccines and original pharmaceutical products, which are presented in 10 countries, including the EAEU, Middle East and EU countries.
Petrovax's is the partner of international Big Pharma companies: Pfizer, Abbott, ISU ABXIS, Adimmune, Hengrui. The company's investment strategy is aimed at investigation, production development and import substitution of medicines and vaccines used in the treatment of socially significant conditions, such as oncological, autoimmune, infectious, and orphan diseases.
Founded in 1996, Petrovax Pharm has demonstrated strong capabilities in research, development, and manufacturing in the biopharmaceutical industry. With a diverse product portfolio, international partnerships, and a focus on R&D, Petrovax presents an opportunity for investors seeking exposure to the biotech and pharmaceutical sectors.
